AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01237444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir plus one nucleoside
Description: ARM 1:~Lopinavir/ritonavir 200mg/50mg 2 tabs bid plus 3TC 150mg x1 tab bid
Study NCT01237444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lopinavir /ritonavir plus two nucleosides
Description: ARM 2:~3TC 150mg x1 tab bid or FTC 200mg 1 capsule qd plus Lopinavir/ritonavir 200mg/50mg 2 tabs BID plus a second NRTI, selected at investigator's discretion, based on baseline genotype.
Study NCT04298086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Treatment
Description: Exercise treatment will consist of individualized walking delivered up to 7 times weekly to achieve the patient-specific goal energy expenditure. Training sessions will be performed on a treadmill at under remote surveillance using a telemedicine approach (i.e.,TeleEx) established in the Exercise-Oncology (ExOnc) Service.
Study NCT04298086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plant-Based Diet
Description: Pre-prepared meals, including 6 dinners and 6 lunches per week, will be shipped to the partipant's home during the intervention.
Study NCT04298086 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Description: Treadmills and low-calorie recipes will be provided to patients in the counseling arm.
Study NCT04298086 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition counseling
Description: Nutrition program including regular counseling by exercise physiologists and registered dieticians (RDs).
Study NCT04298086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Replication Exercise Test
Description: Exercise capacity will be reassessed by a replication exercise test at week 6 in the intervention group only.
Study NCT00004933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydroxyurea
Description: 0.5 to 5 grams PO per day
Study NCT00004933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Homoharringtonine
Description: 2.5 mg/ sq m/ day CIVI for 14 days
Study NCT01293097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 80mg/d ×2d before PCI. After PCI, atorvastatin 40mg/d until 30 days later, and then followed by usual care
Study NCT02114203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for PDE9i
Description: oral dose, every 12 hours for 28 days
Study NCT04274465 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: digital PCR (dPCR) assay
Description: It is a highly sensitive and specific droplet digital PCR assay for absolute quantification of circulating tumor HPV DNA for the most prevalent HPV types that will determine if a woman has cHPVDNA
Study NCT03008473 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: video laryngoscope and chest CT iminge
Study NCT03008473 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional intubation of uniblocker
Study NCT02465047 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-help booklet
Description: See Arm/Group Description
Study NCT01148420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone 17-Acetate
Description: Medroxyprogesterone 20mg orally 3 times a day for 3 days
Study NCT01148420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: medroxyprogesterone acetate
Description: Depo Provera 150mg Intramuscular injection
Study NCT04968145 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home To Stay Mobile Health Application
Description: Home to stay is an integrated discharge monitoring system with a mobile application. Features of the application include a Daily Health Check to report on post-operative recovery, picture taking capability to photograph incisions/wounds and educational information on post-operative care at home.~Patients will complete a Daily Health Check on post-discharge Day #1-14, #21 and #30. The Daily Health Check consists of a series of questions specific to colorectal surgery as well as the Quality of Recovery (QoR-15) questionnaire. After completion, the participant will receive a list of recommendations tailored to their responses including relevant education modules, to contact the surgical team or in urgent cases to go to the nearest emergency room. The participants' responses will be monitored daily via a secure web site. Any participants' responses in the extreme ranges are automatically red flagged and notify the health care team that a follow up telephone call is required.
Study NCT04026451 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sedation guided by SEF95 (10-13 Hz) from SedLine® monitor
Description: Dosage of propofol and fentanyl will be guided by SEF95 value between 10-13 Hz. If SEF95 is lower than 10 Hz, the infusion rate of propofol and fentanyl will be diminished; if SEF95 is higher than 13 Hz, the infusion rate of propofol and fentanyl will be increased; and if SEF95 is between 10-13 Hz, then the infusion rate will be kept.
Study NCT04026451 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sedation guided by SAS scale (1-2)
Description: Dosage of propofol and fentanyl will be guided by SAS to keep a value of 1-2. If SAS is higher than 1-2, then the infusion rate of propofol and fentanyl will be increased; and if SAS is 1-2, then the infusion rate of propofol and fentanyl will be maintained.
Study NCT04026451 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sedation guided by SAS scale (1-2)
Description: Dosage of propofol and fentanyl will be guided by SAS to keep a value of 1-2. If SAS is higher than 1-2, then the infusion rate of propofol and fentanyl will be increased; and if SAS is 1-2, then the infusion rate of propofol and fentanyl will be maintained.
Study NCT04026451 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deep sedation with propofol andfentanyl
Description: Propofol and fentanyl will be infused to reach a score in the SAS of 1-2
Study NCT04026451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deep sedation with propofol andfentanyl
Description: Propofol and fentanyl will be infused to reach a score in the SAS of 1-2
Study NCT04026451 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Ventilation
Description: Critically ill patients will be ventilated mechanically following the clinical indication.
Study NCT04026451 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mechanical Ventilation
Description: Critically ill patients will be ventilated mechanically following the clinical indication.
Study NCT01783782 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DIET
Description: clear liquid diet for 12 hours on the day before CE, followed by an overnight fast
Study NCT01783782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polyethylene glycol 4000 solution with simethicon
Description: patients received a high volume regime consisting of a 50 mL/Kg (up to 2 Lt/die) of PEG solution the evening before the examination, followed always by an overnight fast
Study NCT01783782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simethicon
Description: Patients received 20 mL oral simethicone (Panamir, DMG, Italy, containing 40 mg simethicone in 1mL emulsion) and 200mL water 30 minutes before capsule ingestion
Study NCT04679025 — intervention group
Intervention type: OTHER
Intervention: Exposure - postoperative hyperglycemia
Description: Postoperative hyperglycemia (blood or capillary glucose > 10.0 mmol/L) within 72 hours of a surgical procedure
Study NCT04132466 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Defibrillation using the ASSURE wearable cardioverter defibrillator therapy delivered via a waveform delivery test system
Description: defibrillation using a 170 joule biphasic truncated exponential waveform designed for the ASSURE wearable cardioverter defibrillator
Study NCT04986813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid injection
Description: 1 g of TXA in 100 ml of normal saline
Study NCT04986813 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 100 ml
Study NCT02444377 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interval training
Study NCT00305682 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: anti-thymocyte globulin
Description: Equine ATG dose is 15 mg/kg intravenously (IV) every 12 hours for 6 doses on days -6, - 5, and -4.
Study NCT00305682 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Cyclophosphamide 50mg/kg x 1 to be administered IV over 2 hours with high volume fluid flush on day -6.
Study NCT02834442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-7117
Study NCT02834442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03418207 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: trans-perineal template-guided mapping biopsy
Description: new super saturation of prostate biopsy technique
Study NCT01553500 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: glucomannan
Description: glucomannan is administered at dosage of 5g/day in form of biscuits (6 biscuits/day)
Study NCT01553500 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: lifestyle intervention
Description: hypocaloric diet (25-30 Kcal/kg/day) or isocaloric (40-45 Kcal/kg/day) and physical activity
Study NCT03112369 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy (NET)
Description: An international evidence-based program (EBP) for PTSD based on exposure therapy, an oral tradition of story-telling, and use of tactile medium of natural elements.
Study NCT03112369 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing w/Skills Training (MIST)
Description: Motivational interviewing (MI) coupled with skills training is based on enhancing motivation to change and building skills to address substance use behaviors.
Study NCT00305682 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: Fludarabine 40 mg/m2/day or 30 mg/m2/day intravenously (IV) as one hour infusion x 5 days, on day -6 to -2.
Study NCT00305682 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil
Description: Mycophenolate mofetil (MMF) 3 gram/day for patients who are ≥ 40 kg divided in 2 or 3 doses. Pediatric patient (\<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours.
Study NCT00893581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine & Placebo
Description: Bipolar adolescents will be initiated on 100 mg per day of quetiapine (or placebo) and 30 mg/kg (maximum starting dose of 600 mg twice daily) of lithium carbonate (or placebo), depending on randomization assignment. Patients will be given placebo for the medication to which they were not assigned. Quetiapine will be adjusted based on tolerability and response to a target dose of 400-600 mg and lithium will be adjusted to a target dose based on achieving a serum level of 1.0-1.2 mEq/L.
Study NCT00893581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium and Placebo
Description: Bipolar adolescents will be initiated on 100 mg per day of quetiapine (or placebo) and 30 mg/kg (maximum starting dose of 600 mg twice daily) of lithium carbonate (or placebo), depending on randomization assignment. Patients will be given placebo for the medication to which they were not assigned. Quetiapine will be adjusted based on tolerability and response to a target dose of 400-600 mg and lithium will be adjusted to a target dose based on achieving a serum level of 1.0-1.2 mEq/L.
Study NCT00893581 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Healthy Controls
Description: Healthy control (patients given placebo -- sugar pill intended to mimic drug)
Study NCT02585102 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Recommended Vegetable Intake
Description: Subjects will consume vegetables in amounts recommended by the Dietary Guidelines for Americans
Study NCT02585102 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Vegetable Intake
Description: Subjects will consume vegetables in their usual amount
Study NCT01654250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NWP09
Description: Methylphenidate, variable dose, daily dosing, 1 week duration
Study NCT01654250 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04430621 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Follicle Stimulating Hormone
Description: FSH will be administered s.c. in the morning to male healthy subjects
Study NCT04430621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follicle Stimulating Hormone
Description: FSH will be administered s.c. in the morning to male healthy subjects
Study NCT00795795 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preimplantation Genetic Screening
Description: Preimplantation Genetic Screening
Study NCT00795795 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVF without PGS
Description: IVF without PGS
Study NCT00660959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lixivaptan
Description: oral capsule
Study NCT00660959 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral capsule
Study NCT03845673 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Psyllium
Description: Psyllium fiber (Konsyl; Konsyl Pharmaceuticals, Easton, Md)
Study NCT03845673 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bowel recipe
Description: consisted of 1 cup of unprocessed wheat bran, 1 cup of applesauce, and 1/4 cup of prune juice.
Study NCT00148538 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance and/or Aerobic Exercise
Description: Resistance and/or Aerobic Exercise
Study NCT01230814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate)
Description: Neo-Penotran® Forte (active ingredient Metronidazole \& Miconazole Nitrate), co-formulated vaginal suppositories containing metronidazole 750 mg with miconazole 200 mg and excipients (Witepsol S 55). Witepsol S 55 is a hard fat suppository base. Such bases consist mainly of triglyceride esters of the higher saturated fatty acids along with varying proportions of mono- and diglycerides. 117 subjects receive nightly for 5 consecutive night each month.
Study NCT01230814 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo vaginal suppositories, identical in appearance to the active product; contains Witepsol S 55, Titanium Dioxide and D+C yellow #10 with no metronidazole or miconazole.117 subjects receive nightly for 5 consecutive nights each month.
Study NCT02738697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Description: 8\~12 cycles of adjuvant chemotherapy with FOLFOX were performed 4-6 weeks after radical surgery
Study NCT02738697 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Follow-up
Description: Patients received just follow-up instead of adjuvant chemotherapy
Study NCT04138082 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exposition to high-dB soundtrack
Description: Already stated
Study NCT01293097 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Statin
Description: Usual care, but statin dose should not be higher than that described in exclusion criteria
Study NCT01741545 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated-Interferon-lambda
Study NCT02759263 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cogmed Working Memory Training
Description: Cogmed Working Memory Program will be used as a computerized home-based intervention. Families will receive a link for downloading a web-based software program. The program will be installed on a computer at a family's home by a research assistant. Parents and adolescents will be actively involved, and during the installation session, adolescents will complete several practice trials. The 25 sessions will be completed individually by the adolescent with parental supervision. For the first 5 sessions, the participant trains on the same set of games; on the 6th session and every 5th session thereafter, a new task is introduced and replaces one of the initial tasks. At the end of each session, the adolescent can play an age-appropriate computerized game as a reward. After each session, results are uploaded by parents to a secure website, to keep track of the participant's progress. Families will be contacted weekly to check program function and discuss concerns.
Study NCT03699800 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graphomotor intervention program
Description: The graphomotor intervention program aims to promote the development and reinforcement, different skills involved in the learning process of handwriting and has a preventive character. It follows a bodily, playful, multisensory, exploratory (sensory integration) and neuromotor task training approach and focuses on the following intervention domains: segmental awareness, passive relaxation, trunk-limb dissociation, interdigital coordination, attention, planning, spatial organization/orientation and perception.
Study NCT03517020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torrent's Nebivolol Tablets
Study NCT03517020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Forest Pharmaceuticals Inc's Bystolic Tablets
Study NCT04928066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iguratimod
Description: Iguratimod tablet，25mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
Study NCT04928066 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tofacitinib
Description: Tofacitinib,5mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
Study NCT04928066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: Tofacitinib,5mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
Study NCT04928066 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pred
Description: Pred, 0-10mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response.
Study NCT04928066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pred
Description: Pred, 0-10mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response.
Study NCT02846454 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: inulin
Description: Investigate the satiating effects of consuming 4g/d inulin in 2 daily doses of 2g
Study NCT02846454 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: arabinoxylan
Description: Investigate the satiating effects of consuming 4g/d arabinoxylan in 2 daily doses of 2g
Study NCT03420963 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cord Blood-derived Expanded Allogeneic Natural Killer Cells
Description: Given IV
Study NCT03420963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT03420963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT03828669 — intervention group
Intervention type: BEHAVIORAL
Intervention: Recovery Toolkits
Description: Recovery Toolkits are presented to patients in a branded bag and include a brochure, a self-help behavioral pain medicine book, a downloadable app, earbuds, and access to digital behavioral medicine (the My Surgical Success program including online educational videos)
Study NCT00305682 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: umbilical cord blood transplantation
Description: One or 2 UCB units may be infused to achieve the required cell dose.
Study NCT00305682 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: total body irradiation
Description: Administered Day -1, 200 cGy
Study NCT01741545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Study NCT01741545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Study NCT02792816 — intervention group
Intervention type: DRUG
Intervention: First line antimalarial in Myanmar (artemether-lumefrantrine, dihydroartemisinin-piperaquine, and artesunate-mefloquine)
Description: Being a observational cohort study, one of the ACT was selected in each study site to assess the efficacy and safety.
Study NCT02570828 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal Imaging
Description: FLIR ONE attachment to an iPhone
Study NCT03499665 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PNF, Myofascial Releasing Maneuvers, Home Exercise Group
Description: For Group 1 (n:20), the PNF, myofascial releasing and home exercises were used to decrease pain, jaw restriction and improve functional mobility on the masseter, lateral and medial pterygoid, buccinator, temporalis, orbicularis oris, orbicularis oculi, upper side of trapezius muscle, splenius, scalenous, and cervical extensor muscle in 20 patients with bruxism, for 2 and 6 weeks after pre-evaluation. PNF, myofascial releasing and home exercises were administered for 2 weeks, followed by 3 sets of 10 repeat home exercises and 6 weeks under physiotherapist control.